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We present the first systematic evidence for the origins of 1/f -type temporal scaling in human
heart rate. The heart rate is regulated by the activity of two branches of the autonomic nervous
system: the parasympathetic (PNS) and the sympathetic (SNS) nervous systems. We examine
alterations in the scaling property when the balance between PNS and SNS activity is modified,
and find that the relative PNS suppression by congestive heart failure results in a substantial increase
in the Hurst exponent H towards random walk scaling 1/f2 and a similar breakdown is observed
with relative SNS suppression by primary autonomic failure. These results suggest that 1/f scaling
in heart rate requires the intricate balance between the antagonistic activity of PNS and SNS.
PACS numbers: 87.19.Hh, 05.40.-a, 87.80.Vt, 89.75.Da
Healthy human heart rate has long been known to
exhibit 1/f -type fluctuations [1, 2, 3, 4] and has re-
cently also been attributed multifractal scaling properties
[5]. This complex dynamics, resembling non-equilibrium
[6] and/or multi-scale [7] dynamics in physics, has been
demonstrated to be independent of human behavior—the
statistical properties of heart rate remain unaltered even
after eliminating known behavioral modifiers [8, 9]—,
suggesting that the origin of heart rate complexity lies
in the intrinsic dynamics of the physiological regulatory
system. One conjecture previously posed is that 1/f
(global) scaling and local multifractal scaling in heart
rate is caused by the interaction between the activity of
sympathetic (SNS) and parasympathetic (PNS) nervous
systems [2], leading respectively to the increase and the
decrease in heart rate. However, the evidence for this is
scarce [10].
Here, we present the first systematic evidence for the
origins of 1/f scaling and multifractality in human heart
rate. We demonstrate that modifying the relative impor-
tance of either of the two branches leads to a substantial
departure from 1/f scaling, showing that 1/f scaling in
healthy heart rate requires the existence of and the in-
tricate balance between the antagonistic activity of PNS
and SNS. It supports the view of the cardiac neuroreg-
ulation as a system in a critical state [11], and perma-
nently out of equilibrium, in which concerted interplay of
the SNS and PNS is required for preserving momentary
“balance”. This view of cardiac neuroregulation is coher-
ent with a broad class of models of phenomena which, to
a large extent, has been established using the implicit or
explicit concept of balance of competing agents or sce-
narios.
Further, we also observe a hitherto unexplored rela-
tionship between the multifractality of the heart rate and
variability as measured by interval variance. While it
is generally believed that lower variability results in a
reduction of multifractal properties (reduced spectrum
width), as has been demonstrated in relative PNS sup-
pression both by congestive heart failure (CHF) [5] and
by the parasympathetic blocker atropine [8], we observe
conservation of multifractal properties in relative SNS
suppression by primary autonomic failure (PAF) at sub-
stantially reduced variability to levels closer to CHF. This
suggests the relevance of the intrinsic PNS dynamics for
multifractality.
We believe these findings to be important in putting
forward the antagonistic scenario for complex (multi-)
fractal dynamics that has now been observed in a wide
variety of real-world signals and also in helping diagnose
the condition of a range of patients having abnormality
in their autonomic regulatory system.
We analyze three groups of subjects, of whom long-
term heart rate data were measured as sequential heart
interbeat intervals. The first group consists of 115
healthy subjects (26 women and 89 men; ages 16 − 84
yrs) without any known disease affecting autonomic con-
trols of heart rate, who underwent ambulatory monitor-
ing during normal daily life [Fig. 1(a)]. The total num-
ber of whole-day data sets is 181, as some of the subjects
were examined for two consecutive days, with each data
set containing on average 105 heartbeats. Details of the
recruitment of the subjects, screening for medical prob-
lems, protocols and the data collection are described in
Ref. [12]. We analyzed both whole-day data containing
sleep and awake periods and daytime only data, with es-
sentially identical results [13]. In this paper, we present
daytime results only.
The second group of subjects are 12 patients with
CHF, of whom whole-day ambulatory data [Fig. 1(c)] are
2FIG. 1: (Color) Typical traces of daytime heartbeat intervals
for (a) a healthy subject, (b) a PAF patient and (c) a CHF
patient. The color coding used shows the local contribution
to multifractality—the color spectrum is centered at h = 0.3
(green), with the strongest singularities in red (h = 0.0) and
the weakest in blue (h = 0.6) [14].
available from Physionet [15]. This severe heart failure is
known to be associated with both increased SNS [16, 17]
and decreased PNS [16, 18] activity. Thus, this data set
contains information on how heart rate is (multi-) scaled
during relative PNS suppression.
As the last group, we examined the 24-hour ambula-
tory heart rate dynamics of 10 PAF patients aged 54–
77 years [19, 20], containing on average 105 heartbeats
[21] [Fig. 1(b)]. PAF is clinically characterized as au-
tonomic dysfunction, including orthostatic hypotension,
impotence, bladder and bowel dysfunction and sweating
defects, which primarily result from progressive neuronal
degeneration of unknown cause. The main pathological
finding related to autonomic dysfunction in PAF is severe
loss of preganglionic and/or postganglionic sympathetic
neurons [22]. In contrast to the severe degeneration of
the efferent SNS, PNS is believed to remain relatively
intact in PAF; we will confirm this below by showing a
similar level of high-frequency fluctuations of heart rate,
known as a robust indicator of PNS activity [25, 26], in
our PAF patients to that of healthy subjects. Thus, it is
highly possible that this group serves as an example of
relative and neurogenic SNS suppression.
The mean global scaling exponent (the Hurst exponent
H) has been evaluated by using (first order) detrended
fluctuation analysis (DFA) [15, 23, 24]. We have analyzed
the scaling behavior of the mean quantity (group mean)
M¯DFA(s) = L
−1
∑L
l=1 log10(D
(l)
DFA(s)), where l indexes
time series in the group. For each scale/resolution s as
measured by the DFA window size, and for each inte-
grated, normalized heartbeat interval time series {F
(l)
i =
T−1l
∑i
j=1 f
(l)
j }(i=1,...,Nl),(l=1,...,L), D
(l)
DFA(s) (total scale-
10-3
10-2
101 102 103
D
FA
/s
ca
le
scale
CHF            
PAF            
HEALTHY        
slope(H)=0.2   
slope(H)=0.225 
slope(H)=0.09  
FIG. 2: (Color online) Scale dependency of the mean de-
trended fluctuation M¯DFA(s) for healthy subjects, PAF pa-
tients and CHF patients. Detrended fluctuations have been
calculated with first order DFA, i.e. linear trend removal [24].
Vertical bars represent the standard deviations of the group
means.
wise detrended fluctuation) has been calculated:
D
(l)
DFA(s) = s
−1
√√√√ 1
K(l)(s)
K(l)(s)∑
k=1
(F
(l)
k − Pk(s))
2 .
Pk(s) denotes the local least-squares linear fit in each
DFA window k, and K(l)(s) is the number of windows
per scale s. Integration of the input heart rate intervals
is performed according to standard DFA practice, and
the norm used is the elapsed time Tl =
∑Nl
i=1 f
(l)
i . The
normalization applied allows us to compute group aver-
ages of records of different duration, and to compare the
mean absolute levels of variability per resolution s; for
each resolution s, the quantity M¯DFA(s) measures the
(logarithmic) scalewise mean of the normalized DFA—
the sum of the logarithm of detrended fluctuations for
each group of time series at this resolution. The Hurst
exponent was computed from the log-log fit to the group
averaged DFA values over the selected range of scales
(20− 4, 000 beats).
In Fig. 2, we show the scaling behavior of the M¯DFA(s)
versus log10(s) for healthy subjects, PAF patients, and
CHF patients, with the slopes corresponding to the Hurst
exponent H . We find a substantial difference in the
scalewise variability levels between controls and PAF and
CHF patients. This holds for the entire compared reso-
lution range of 4− 4, 000 beats as measured by the DFA
window size s. However, PAF variability reaches normal
levels asymptotically for the highest resolutions (and low-
est beat numbers), most likely reflecting the preservation
of high-frequency fluctuations of heart rate indicative of
the intact PNS activity [25, 26] in our PAF patients.
3CHF variability, on the contrary, remains at low levels at
all resolutions.
In addition, we find that the relative PNS suppression
by CHF results in a substantial increase in the Hurst
exponent from 1/f range (H ≈ 0.09 for healthy con-
trols) to H > 0.2, i.e. towards random walk scaling 1/f2
(H = 0.5) [Fig. 2]. This effect has been observed for the
entire range of resolutions with almost consistent scaling,
which for all three groups stretches from about 20 beats
up to the maximum resolution used of 4,000 beats (DFA
window size). The slope within the scaling range ob-
tained for PAF is close to that obtained for CHF and con-
siderably higher than that for the control group. Thus,
surprisingly, we observe a similar breakdown in the case
of relative and neurogenic SNS suppression by PAF. This
is particularly interesting in the context of the recognized
effect that β-adrenergic blockers, mainly affecting the re-
sponse of the heart to non-suppressed SNS activity and
leaving the vascular branch of sympathetic neuroregula-
tion intact, do not result in a breakdown of 1/f scaling
in heart rate [4, 8].
Further, we also tested the multifractal properties of
the data using the wavelet-based multifractal methodol-
ogy [27]. We apply the 2nd derivative of the Gaussian
to the data as the mother wavelet before calculating the
partition function Zq(s), defined as the sum of the q-th
powers of the local maxima of the modulus of the wavelet
transform coefficients at scale s. The power law scaling
of Zq(s) for 13 < s < 850 then yields the scaling ex-
ponents τ(q)—the multifractal spectrum [Fig. 3]. The
multifractal spectrum is related to the singularity spec-
trum D(h), where D(ho) is the fractal dimension of the
subset of the original time series characterized by a local
Hurst exponent h = ho [28], through a Legendre trans-
form D(h) = qh− τ(q) with h = dτ(q)/dq [Fig. 3, inset].
For both PAF patients and control subjects, we ob-
tained comparable curvature of the τ(q). However, this
curvature is nearly lost in the case of CHF patients
[Fig. 3]. These results imply wider singularity spectra
D(h) for both PAF patients and control subjects, indica-
tive of preserved multifractality [Fig. 3, inset], that can
also be observed in non-uniform distributions of the local
Hurst exponents h [Fig. 1]. In addition, we also observe
an intriguing relation between the conserved multifractal-
ity of the heart rate for the PAF case and the profoundly
low absolute variability as measured by normalized DFA
[Fig. 2]. While it is generally believed that lower variabil-
ity results in a reduction of multifractal properties (re-
duced spectrum width), as has been demonstrated in rel-
ative PNS suppression both by CHF [5] and the parasym-
pathetic blocker atropine [8], in PAF patients we observe
conservation of multifractal properties at substantially
reduced variability to the levels closer to CHF. This sug-
gests the relevance of the intrinsic PNS dynamics for the
multifractality of heart rate.
Amaral et al. [8] reported a slightly decreased width
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FIG. 3: (Color online) Multifractal (τ (q)) spectra for healthy
subjects, PAF patients, and CHF patients. Vertical bars rep-
resent the standard deviations of the linear fit to (the group
mean of) the partition function. (Inset) Singularity (D(h))
spectra derived from the avarage τ (q) curves.
of multifractal spectra and an almost unchanged global
scaling exponent of healthy heart rate during the admin-
istration of the sympathetic blocker metoprolol , which
reduces sympathetic control by blocking the action of β-
adrenergic receptors on the heart. Physiologically, this
case is very different from PAF because in healthy sub-
jects, central SNS activity also influences vascular tone
of both capacitance and resistance vessels through α-
adrenergic mechanisms, and strongly affects blood pres-
sure (through cardiac output and peripheral resistance)
and hence heart rate through baroreflex control with the
intact PNS. In other words, while the metoprolol only
blocks the β-adrenergically mediated effects of SNS on
the heart in healthy subjects, PAF is associated with a
wide range of sympathetic failure affecting various end-
organs including the heart and the vasculature [22], and
the breakdown of 1/f scaling of heart rate is observed
only in the latter case. Thus, we conclude that healthy
1/f heart rate indeed requires physiologically antagonis-
tic activity of PNS and SNS within the brain for auto-
nomic neuroregulation.
A relevant question would be why “nature” has im-
plemented an antagonistic control system in one of, if
not the, most important instruments in maintaining hu-
man life, i.e. the heart. One possible, albeit as of
now still speculative explanation is that the antagonis-
tic control prevents mode locking by ensuring perma-
nent far-from-equilibrium-like, critical state-like opera-
tion [6], and thus enhances error tolerance of the sys-
tem [29]. The importance of this invariant “response”—
mode-free operation—may be the result of the optimiza-
tion of the heart rate control system by evolutionary
processes; physiologically antagonistic cardiac control is
4observed in a wide range of vertebrates [30]. A mode-
free response may be important for rapid change of the
operating point of the system according to dynamically
changing internal and/or external environmental condi-
tions.
Historically, measurements of fluctuations of heart rate
have been widely used for monitoring human autonomic
controls in health and disease [25, 26]. In particular, the
heart rate can easily be measured during normal daily
life, by ambulatory monitoring devices, enabling us to
probe various autonomic pathologies in a natural set-
ting. However, one drawback of this method using short-
term fluctuations of heart rate such as spectral analyses
[25, 26] is that the statistical properties of heart rate
may be affected by behavior (e.g. exercise, diet, postu-
ral changes, etc.), as well as by pathological changes in
the autonomic nervous system. It is usually very diffi-
cult to monitor patients’ behavior during normal daily
life, and robust identification of autonomic abnormality
due to the disease per se is difficult. By contrast, the
long-term (multi-) scaling properties of ambulatory heart
rate have recently been shown to be highly independent
of behavioral modifiers [8, 9]. This study further shows
that the scaling properties do depend on the autonomic
pathologies of patients, i.e. one may be able to derive a
behavioral-independent marker for PNS suppression by
the increased global scaling exponent and the decreased
multifractality of heart rate, and for SNS suppression by
the increased global exponent, but with preserved multi-
fractality. Thus, our findings could be also important in
helping diagnose a range of patients having abnormality
in their autonomic regulations.
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